- Home
- MKTW vs CNTX Comparison
MKTW vs CNTX Comparison
Compare MKTW & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MKTW | CNTX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3M | 47.7M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MKTW | CNTX |
|---|---|---|
| Price | $19.67 | $0.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | ★ $23.76 | $4.14 |
| AVG Volume (30 Days) | 16.5K | ★ 971.2K |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | ★ 9.19% | N/A |
| EPS Growth | ★ 1183.33 | 17.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $512,403,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.49 | $0.22 |
| 52 Week High | $22.83 | $3.62 |
Technical Indicators
Market Signals| Indicator | MKTW | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 29.57 |
| Support Level | $19.19 | N/A |
| Resistance Level | $21.05 | $0.36 |
| Average True Range (ATR) | 0.69 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 81.30 | 23.87 |
Price Performance
Historical ComparisonAbout MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.